Dr. Sznol Describes Nivolumab in Advanced Melanoma

June 2, 2013

Conference | ASCO Annual Meeting

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

Mario Sznol, MD, a professor of medical oncology at the Yale Cancer Center in New Haven, Connecticut, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

This is the first analysis to demonstrate a survival advantage for treatment with nivolumab in previously treated melanoma, Sznol notes. The median overall survival for the 107 patients on the trial was 16.8 months and the objective response rate was 31% with a median duration of response of nearly two years. Moreover, Sznol notes, patients responded rapidly and continued to respond even after treatment had been stopped.